Mural Oncology (NASDAQ:MURA) Receives “Hold” Rating from Jones Trading

Jones Trading reissued their hold rating on shares of Mural Oncology (NASDAQ:MURA) in a report released on Tuesday, Marketbeat Ratings reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a report on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Mural Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Mural Oncology Stock Up 1.5 %

Shares of Mural Oncology stock opened at $1.35 on Tuesday. The business’s fifty day simple moving average is $3.77 and its 200-day simple moving average is $3.58. The firm has a market cap of $23.26 million, a PE ratio of -0.15 and a beta of 3.66. Mural Oncology has a 52 week low of $1.28 and a 52 week high of $5.12.

Mural Oncology (NASDAQ:MURA) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.96) by ($0.05). During the same quarter last year, the business posted ($3.57) EPS. As a group, equities analysts expect that Mural Oncology will post -7.54 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Commerce Bank acquired a new stake in shares of Mural Oncology in the 3rd quarter valued at $39,000. FMR LLC lifted its holdings in Mural Oncology by 124.7% during the 3rd quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after buying an additional 11,423 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Mural Oncology during the 3rd quarter worth about $340,000. Geode Capital Management LLC boosted its position in shares of Mural Oncology by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock worth $595,000 after acquiring an additional 4,731 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Mural Oncology in the 4th quarter valued at about $181,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.